Does the Simultaneous Introduction of Several Pharmaceuticals in the Post-Lenalidomide Era Translate to Better Outcomes in Relapse Refractory Multiple Myeloma? Findings from the Real-World Innovation in Multiple Myeloma (REAL IMM) Study.

However, a clear trend in favor of daratumumab-based schemes could be observed ( Figure 2 c).

also in 19,460 other papers

There has been an increasing trend in the global MM incidence, with an age-standardized rate of 1.78 per 100,000 people estimated in 2020 [ 2 ].

also in 63,971 other papers